Gilead Sciences Inc. on Tuesday sued to stop a rival drugmaker from bringing a generic version of Sovaldi to market, as the company continues its campaign to protect the hepatitis C treatment amid rapidly declining sales.
The 26-count complaint, filed in the U.S. District Court for the District of Delaware, accused Israeli-based Teva Pharmaceutical Industries Ltd. and its U.S. subsidiary of infringing 17 patents for the drug, which is used to treat adult and teens suffering from chronic hepatitis C infection.
